

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

NOVEN PHARMACEUTICALS, INC.,  
Petitioner

v.

NOVARTIS AG AND LTS LOHMANN THERAPIE-SYSTEME AG,  
Patent Owners

---

*Inter Partes* Review No.: IPR2014-00549

U.S. Patent No. 6,316,023

**REPLY DECLARATION OF CHRISTIAN SCHÖNEICH, PH.D.**

## TABLE OF CONTENTS

	Page
I. QUALIFICATIONS.....	1
II. INFORMATION CONSIDERED.....	1
III. REPLY TO DR. KLIBANOV’S DECLARATION .....	1
A. Dr. Klibanov’s Understanding of a POSA Is Inconsistent with the Clear Teachings in the Art .....	1
B. Dr. Klibanov Misrepresents the State of the Art.....	3
(1.) The Structural Features Affecting Bond Strength and Susceptibility to Oxidation Would Have Been Known to the POSA in 1998 .....	3
(2.) Dr. Klibanov’s Discussion of the Many Types of Physical and Chemical Degradation is Misleading and Unscientific .....	10
C. A POSA Would Have Predicted that Rivastigmine Would Be Susceptible to Oxidative Degradation.....	12
(1.) Dr. Klibanov’s Definition of “Susceptibility to Oxidation” Fails .....	12
(2.) A POSA Would Have Predicted Susceptibility to Oxidation Based on the Molecule’s Chemical Structure.....	14
a. The prior art demonstrates that a POSA would examine a drug’s chemical structure and reasonably predict the type of degradation (including oxidation) .....	14
b. Dr. Klibanov’s application of functional group chemistry contradicts his opinion that a POSA cannot make predictions based on the presence of functional groups .....	19
(3.) Dr. Klibanov Confuses the Mechanism of Oxidative Degradation with a Compound’s Susceptibility to Oxidation.....	20
(4.) A POSA Would Predict Susceptibility to Oxidation Without Identifying a Rate-Limiting Step.....	25

**TABLE OF CONTENTS**  
(continued)

	<b>Page</b>
(5.) Commercial Formulations Without an Antioxidant Would Not Teach a POSA that the Drug Molecule Was Stable.....	27
(6.) Dr. Klibanov Relies on Drug Molecules that do Not Contain the Combination of Structural Elements that Cause Rivastigmine to be Particularly Susceptible to Oxidative Degradation.....	34
(7.) The Similarities Between the Structures of Nicotine and Rivastigmine and Nicotine’s Known Susceptibility to Oxidation Would Have Supported a POSA’s Understanding that Rivastigmine Is Susceptible to Oxidation.....	37
a. None of the distinctions between the structures of rivastigmine and nicotine raised by Dr. Klibanov make a difference .....	37
b. Linnell teaches that nicotine is susceptible to oxidation at the benzylic carbon.....	41
(8.) Dextromethorphan Was Known to Be Susceptible to Oxidation.....	43
(9.) Comparisons In the Prior Art to Physostigmine Would Not Teach a POSA that Rivastigmine Is Oxidatively Stable.....	45

I, Christian Schöneich, Ph.D., declare and state as follows:

**I. QUALIFICATIONS**

1. For a discussion of my qualification and credentials, I refer to my curriculum vitae (Ex. 1024) and my April 2, 2014 declaration (Ex. 1011), which also provides a list of matters in which I have testified over the last four years, and my compensation.

**II. INFORMATION CONSIDERED**

2. I have reviewed the Declaration of Dr. Klibanov (Ex. 2012) and the documents cited in that report. Dr. Klibanov makes numerous statements in his declaration that are misleading and/or unscientific. I address these statements below.

3. In forming my opinions, I have relied upon my accumulated scientific knowledge and experience. I have reviewed the documents cited in my April 2014 declaration (Ex. 1011), including the documents listed in paragraph 9 of that declaration. I have also reviewed the documents cited in this declaration.

**III. REPLY TO DR. KLIBANOV'S DECLARATION**

**A. Dr. Klibanov's Understanding of a POSA Is Inconsistent with the Clear Teachings in the Art**

4. Dr. Klibanov states that a POSA could not make any predictions about the physical or chemical properties of a compound based on its structure:

I [Dr. Klivanov] disagree that a POSA would be able to make predictions about the physical or chemical properties of a compound based on its chemical structure.

(Ex. 2012 at ¶ 25.) This statement is incorrect. Ordinarily-skilled artisans in 1998 routinely made predictions about the physical/chemical properties of compounds based on chemical structure. (Ex. 1038 at 3.)

5. As I described in my opening report (*see, e.g.*, Ex. 1011 ¶¶ 14-46 in particular ¶¶ 32-35) and discuss below (*see* ¶¶ 7-15), a POSA could also make reasoned predictions about the strength of particular chemical bonds in a drug molecule and the susceptibility of the molecule to degradation, including oxidative degradation. A POSA was instructed by the prior art to assess a molecule's chemical structure and make such determinations during pharmaceutical formulation development. (Ex. 2020 at 110; Ex. 2014 at 181, in particular *see* ¶¶ 23-25 below.)

6. Indeed, Dr. Klivanov confirms the predictive value of chemical structure analysis. In his declaration, Dr. Klivanov states that a POSA could predict a molecule's susceptibility to hydrolysis based on whether it contained a monomethyl or a dialkyl carbamate functional group. Dr. Klivanov states that monomethyl carbamates in general were known to degrade by hydrolysis (Ex. 2012 ¶ 82) and "dialkyl carbamates were hydrolytically stable" (Ex. 2012 ¶ 86).

These statements are inconsistent with the above statement by Dr. Klivanov that a

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.